<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <title>Fusiomica – AI-designed proteins</title>
    <link rel="preconnect" href="https://fonts.googleapis.com" />
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin />
    <link href="https://fonts.googleapis.com/css2?family=Poppins:wght@400;600;700&display=swap" rel="stylesheet" />
    <link rel="stylesheet" href="styles.css" />
</head>
<body>
    <!-- Navigation bar -->
    <nav class="navbar">
        <div class="container nav-container">
            <a href="#hero" class="logo">Fusiomica</a>
            <!-- Mobile hamburger toggle -->
            <div class="menu-toggle" onclick="toggleMenu()">
                <span></span>
                <span></span>
                <span></span>
            </div>
            <ul class="nav-links">
                <li><a href="#technology">Technology</a></li>
                <li><a href="#offer">Our Offer</a></li>
                <li><a href="#case">Case Study</a></li>
                <li><a href="#applications">Applications</a></li>
                <li><a href="#pipeline">Pipeline &amp; PET</a></li>
                <li><a href="#contact">Contact</a></li>
            </ul>
        </div>
    </nav>

    <!-- Hero section with gradient background -->
    <header id="hero" class="hero-section">
        <div class="container hero-content">
            <img src="assets/fusiomica_logo.png" alt="Stylized molecular structure..." class="hero-logo logo-negative" />
            <h1 class="hero-title">AI-designed proteins for a new era of medicine</h1>
            <p class="hero-subtitle">
                Fusiomica harnesses advanced protein design to create
                <em>de&nbsp;novo</em> binders that diagnose and treat disease with
                unprecedented precision and speed.
            </p>
            <a href="#contact" class="btn-primary">Work with us</a>
        </div>
    </header>

    <!-- Technology section -->
    <section id="technology" class="section">
        <div class="container">
            <h2>Technology — How It Works</h2>
            <p>
                Fusiomica is a protein engineering company specialising in the
                design of <em>de&nbsp;novo</em> mini-protein binders. Leveraging
                state-of-the-art genAI algorithms, we generate ultra-stable, high-affinity proteins
                that bind targets inaccessible to antibodies. Unlike natural
                antibodies (~150&nbsp;kDa), our binders are 8–15&nbsp;kDa, enabling
                rapid tissue penetration, fast clearance and precise
                targeting. They are produced in <em>E.&nbsp;coli</em> at very high yields and remain folded up to 95&nbsp;°C. A single
                engineered cysteine permits site-specific <strong>conjugation</strong> of
                radionuclides, fluorophores or drugs. The result is a
                versatile platform that delivers cost-effective imaging
                probes, biopharmaceuticals, diagnostic and research reagents.
            </p>
            <img src="assets/difussion.png" alt="Diffusion model illustration" style="display:block; margin: 2rem auto 2rem auto; width:100%; height:auto;" />
            <div class="grid two-columns">
                <div>
                    <h3>Why <em>de&nbsp;novo</em> binders?</h3>
                    <ul class="bullet-list">
                        <li><strong>Precision design.</strong> Exact binding sites are built <i>in silico</i> for tailored target recognition.</li>
                        <li><strong>Cost-effective production.</strong> Bacterial expression yields monomeric proteins at a fraction of mammalian culture costs.</li>
                        <li><strong>Enhanced penetration.</strong> Small size facilitates access to densely packed tissues and across biological barriers.</li>
                        <li><strong>Superior stability.</strong> AI-optimised hydrophobic cores confer high thermostability and resistance to denaturants.</li>
                        <li><strong>Simplified IP.</strong> Synthetic sequences avoid crowded antibody patent landscapes.</li>
                        <li><strong>De-immunisation.</strong> Designs screened to remove MHC&nbsp;II binding sequences.</li>
                    </ul>
                </div>
                <div>
                    <h3>How we design</h3>
                    <ul class="bullet-list">
                        <li><strong>Generative scaffolding.</strong> Diffusion models propose shape-complementary folds to target epitopes.</li>
                        <li><strong>Physics-aware filters.</strong> Interface ΔG, buried surface area, shape complementarity and H-bond satisfaction.</li>
                        <li><strong>Sequence optimisation.</strong> ProteinMPNN-style redesign for expression, stability and solubility.</li>
                        <li><strong>Manufacturability gates.</strong> Cys placement for site-specific conjugation and de-immunisation screens.</li>
                    </ul>
                </div>
            </div>
        </div>
    </section>

    <!-- Our Offer section -->
    <section id="offer" class="section alt-background">
        <div class="container">
            <h2>Our Offer</h2>
            <p>
                We partner with pharmaceutical, biotech and diagnostic organisations to design bespoke binders and deliver experimentally validated constructs. Engagement models include fee-for-service, shared-risk with success fees, and full IP transfer.
            </p>
            <div class="grid three-columns">
                <div class="card" style="text-align: center">
                    <img src="assets/binder_disc.png" alt="Binder discovery" style="height:96px;display:block;margin:0 auto 1rem auto;" />
                    <h3>Binder Discovery</h3>
                    <p>
                        Computational generation of hundreds to thousands of
                        candidate binders using structure-guided design and
                        deep generative models. Rigorous in-silico screening
                        identifies hits with desired epitope specificity.
                    </p>
                </div>
                <div class="card" style="text-align: center">
                    <img src="assets/production.png" alt="Production" style="height:96px;display:block;margin:0 auto 1rem auto;" />
                    <h3>Hit&nbsp;to&nbsp;Lead</h3>
                    <p>
                        Expression and purification in <em>E.&nbsp;coli</em>,
                        followed by binding assays (HPLC, SPR, ELISA) to
                        confirm on-target affinity. Lead molecules are
                        affinity-matured to sub-nanomolar range and assessed
                        for stability, solubility and manufacturability.
                    </p>
                </div>
                <div class="card" style="text-align: center">
                    <img src="assets/labeling.png" alt="Labeling/Functionalisation" style="height:96px;display:block;margin:0 auto 1rem auto;" />
                    <h3>Functionalisation</h3>
                    <p>
                        Site-specific conjugation of radionuclides,
                        fluorophores or payloads via engineered cysteines or
                        unnatural amino acids. Fusion to Fc domains extends
                        half-life when required. Final constructs are ready
                        for pre-clinical imaging, therapeutic or diagnostic
                        applications.
                    </p>
                </div>
            </div>
        </div>
    </section>

    <!-- Case study section -->
    <section id="case" class="section">
        <div class="container">
            <h2>Case&nbsp;Study: Patent-Pending Probe generated in weeeks</h2>
            <div class="grid two-columns">
                <div>
                    <p>
                        To showcase the power of our platform, we pursued a
                        self-funded proof-of-concept programme against a
                        challenging cancer marker (“Target&nbsp;1”). With a
                        limited bootstrapped budget, our scientists generated
                        multiple binder designs <i>in&nbsp;silico</i> and synthesised
                        the top candidates. Experimental testing confirmed
                        binding for more than 40&nbsp;% of the designs. The
                        selected binder exhibits nanomolar affinity, no
                        unfolding up to 95&nbsp;°C. Production in
                        <em>E.&nbsp;coli</em> yields &gt;100&nbsp;mg·L⁻¹ of pure protein.
                    </p>
                    <p>
                        A single cysteine residue, absent from the natural
                        scaffold, allows site-specific attachment of
                        radionuclides, fluorophores or cytotoxins.
                        This binder forms the basis of a European patent
                        application (<strong>EP25461534</strong>). The entire
                        project was executed 10× cheaper and 80&nbsp;% faster
                        than a comparable antibody discovery campaign.
                    </p>
                </div>
                <div>
                    <h3 class="highlight-title">Project Highlights</h3>
                    <ul class="bullet-list">
                        <li><strong>Bootstrapped funding.</strong> 100&nbsp;%
                            company-funded.</li>
                        <li><strong>Major unmet need.</strong> Target
                            associated with millions of patients per year.</li>
                        <li><strong>&gt;40&nbsp;% hit rate.</strong> High
                            confirmation rate from in-silico design to wet lab.</li>
                        <li><strong>Patent pending.</strong> Composition-of-matter and use claims.</li>
                        <li><strong>Scalable platform.</strong> Lessons
                            generalise across our pipeline.</li>
                    </ul>
                </div>
            </div>

            <!-- Experimental validation moved here -->
            <h3 class="highlight-title">Experimental Validation</h3>
            <p>
                Representative data show purity, binding kinetics and thermostability (target labels redacted).
            </p>
            <div class="validation-grid">
                <div>
                    <img src="assets/sds_gel_final.png" alt="SDS-PAGE analysis of purified binder and complex" class="fig-image" style="max-height:180px;width:auto;display:block;margin:0 auto 1rem auto;" />
                    <p class="figure-caption"><strong>Purity assessment.</strong> Coomassie-stained SDS-PAGE confirms single bands at expected molecular weights.</p>
                </div>
                <div>
                    <img src="assets/sec.png" alt="Size exclusion chromatography trace" class="fig-image" style="max-height:180px;width:auto;display:block;margin:0 auto 1rem auto;" />
                    <p class="figure-caption"><strong>Monodispersity.</strong> Analytical SEC shows a sharp main peak with minimal aggregation.</p>
                </div>
                <div>
                    <img src="assets/mst.png" alt="MicroScale Thermophoresis binding traces" class="fig-image" style="max-height:180px;width:auto;display:block;margin:0 auto 1rem auto;" />
                    <p class="figure-caption"><strong>Equilibrium binding.</strong> MST traces and binding isotherm demonstrate nanomolar affinity with saturable behaviour.</p>
                </div>
            </div>
        </div>
    </section>

   <!-- Applications section -->
<section id="applications" class="section">
  <div class="container">
    <h2>Applications</h2>
    <div class="grid cards-2col">
      <div class="card">
        <img src="assets/gpcr.png" alt="GPCR-targeted" style="height:128px;display:block;margin:0 auto 1rem auto;" />
        <h3>GPCR-targeted Binders</h3>
        <p>GPCR epitopes are buried in flexible extracellular loops and adopt multiple conformations. Our mini-proteins penetrate these loops and can stabilise specific receptor states or block ligand binding.</p>
      </div>
      <div class="card">
        <img src="assets/biosensor.png" alt="Diagnostic/Biosensor" style="height:128px;display:block;margin:0 auto 1rem auto;" />
        <h3>Diagnostic Reagents</h3>
        <p>Binders are ideally suited where stability, specificity and ease of production are essential.</p>
      </div>
      <div class="card">
        <img src="assets/cart.png" alt="CAR-T" style="height:128px;display:block;margin:0 auto 1rem auto;" />
        <h3>CAR-T Cell Engineering</h3>
        <p>De&nbsp;novo binders offer compact, human-sequence-free recognition domains for cell therapies.</p>
      </div>
      <div class="card">
        <img src="assets/bispecific.png" alt="Bispecifics" style="height:128px;display:block;margin:0 auto 1rem auto;" />
        <h3>Bispecific &amp; Multispecific Formats</h3>
        <p>Combining multiple <em>de&nbsp;novo</em> binders enables advanced bispecific, multispecific, and bifunctional molecules.</p>
      </div>
      <div class="card">
        <img src="assets/dual_adc.png" alt="ADC Formats" style="height:128px;display:block;margin:0 auto 1rem auto;" />
        <h3>ADC Formats</h3>
        <p>Site-specific cysteine engineering enables precise conjugation of cytotoxic payloads for targeted therapies.</p>
      </div>
      <div class="card">
        <img src="assets/fusion.png" alt="Fusion Proteins" style="height:128px;display:block;margin:0 auto 1rem auto;" />
        <h3>Fusion Proteins &amp; Functional Extensions</h3>
        <p><em>De&nbsp;novo</em> binders can be fused to additional domains to add new biological functions or pharmacological properties.</p>
      </div>
    </div>
  </div>
</section>

    <!-- Pipeline section (kept) -->
    <section id="pipeline" class="section">
        <div class="container">
            <h2>Pipeline</h2>
            <p>
                We are advancing a diversified portfolio of binder programs, each representing a high-value opportunity in oncology or immunology. Our goal is to develop these <em>de&nbsp;novo</em> binders into next-generation PET probes and theranostics, enabling targeted imaging and therapy.
            </p>
            <img src="assets/pet_image.png" alt="PET imaging illustration" style="display:block;margin:2rem auto 2rem auto;max-width:400px;width:100%;height:auto;" />
            <div class="pet-panel">
                <h3 class="highlight-title"><i>De novo</i> binders as PET Probes &amp; Theranostics</h3>
                <p>
                    Our <em>de&nbsp;novo</em> binders are being developed into targeted PET probes that act like a molecular biopsy. These small, stable proteins enable same-day, high-contrast imaging and can be converted into theranostic agents by swapping the imaging isotope for a therapeutic radionuclide. This approach allows:
                </p>
                <ul class="bullet-list">
                    <li><strong>Whole-body biopsy.</strong> Binding probes map antigen expression across all lesions, guiding therapeutic decisions.</li>
                    <li><strong>Same-day imaging.</strong> Small binders clear rapidly from circulation, permitting high-contrast imaging in less than three hours instead of the multi-day delay required for antibodies.</li>
                    <li><strong>Dual-use modality.</strong> The same binder can deliver therapy by swapping the imaging isotope for a therapeutic radionuclide, creating a theranostic pair.</li>
                    <li><strong>Reduced invasiveness.</strong> By obviating surgical biopsies and lowering radioactive dose, binder-based PET improves patient comfort and safety.</li>
                </ul>
            </div>
            <div class="pipeline-visual">
    <div class="pipeline-row">
        <div class="pipeline-label">
            Target&nbsp;1<br>
            <span class="pipeline-stage">Lead Optimisation</span>
        </div>
        <div class="pipeline-indication">
            Epithelial origin tumours
        </div>
        <div class="pipeline-bar">
            <div class="pipeline-arrow" style="width: 35%;"></div>
        </div>
    </div>
    <div class="pipeline-row">
        <div class="pipeline-label">
            Target&nbsp;2<br>
            <span class="pipeline-stage">Hit Generation</span>
        </div>
        <div class="pipeline-indication">
            Splicing isoform, breast
        </div>
        <div class="pipeline-bar">
            <div class="pipeline-arrow" style="width: 20%;"></div>
        </div>
    </div>
    <div class="pipeline-row">
        <div class="pipeline-label">
            Target&nbsp;3<br>
            <span class="pipeline-stage">Target Selection</span>
        </div>
        <div class="pipeline-indication">
            Gastric cancer
        </div>
        <div class="pipeline-bar">
            <div class="pipeline-arrow" style="width: 15%;"></div>
        </div>
    </div>
</div>
<p class="pipeline-note">
    Note: “Target selection” means prioritisation of new antigens; “Hit generation” is initial binder discovery; “Lead Optimisation” involves affinity, stability and manufacturability engineering.
</p>
        </div>
    </section>

    <!-- EU funded projects banner (inserted above contact) -->
    <section id="eu-funded" class="section">
        <div class="container" style="text-align:center;">
            <h2>EU Funded Projects</h2>
            <img src="FENG_RP_UE_RGBENGPARP.png" alt="EU funded projects" style="max-height:120px;width:auto;display:block;margin:0 auto 1rem auto;" />
            <div class="eu-logos" style="display:flex;justify-content:center;align-items:center;gap:2rem;margin-top:1rem;">
                <img src="shp.png" alt="SHP logo" style="max-height:60px;width:auto;display:block;" />
                <img src="EIT_LOGO.png" alt="EIT logo" style="max-height:60px;width:auto;display:block;" />
            </div>
        </div>
    </section>

    <!-- Contact section -->
    <section id="contact" class="section alt-background">
        <div class="container">
            <h2>Contact&nbsp;Us</h2>
            <p>
                Ready to explore how our binder technology can benefit your
                project? Send us a message and we’ll get back to you shortly.
            </p>
            <div class="contact-details">
                <p><strong>Email:</strong>
                <span id="email-obscured"></span>
                <noscript>contact [at] fusiomica [dot] com</noscript>
            </p>
            <p><strong>Correspondence address:</strong> Szlak 77/222, 31-153 Kraków</p>
            <p><strong>Deliveries address:</strong> MCB UJ, Gronostajowa 7a, 30-387 Kraków | Poland</p>
        </div>
    </div>
</section>

<script>
    // Obscure email from bots
    document.addEventListener("DOMContentLoaded", function() {
        var user = "contact";
        var domain = "fusiomica.com";
        var email = user + "@" + domain;
        var link = document.createElement("a");
        link.href = "mailto:" + email;
        link.textContent = email;
        var span = document.getElementById("email-obscured");
        if (span) span.appendChild(link);
    });
</script>

    <footer class="footer">
        <div class="container">
            <p>
                Fusiomica sp. z o.o.<br>
                NIP: 6762683727 &nbsp;|&nbsp; REGON: 540461266 &nbsp;|&nbsp; KRS: 0001145551 &nbsp;|&nbsp; VAT: PL6762683727
            </p>
        </div>
    </footer>

    <script>
        // Mobile menu toggle functionality
        const navLinks = document.querySelector('.nav-links');
        function toggleMenu() {
            navLinks.classList.toggle('open');
        }
    </script>
</body>
</html>
